Stockscreener 앱 받기
2.79
5.74%
-0.17
시간 외 거래:
2.78
-0.01
-0.36%
전일 마감가:
$2.96
열려 있는:
$2.92
하루 거래량:
1.48M
Relative Volume:
1.19
시가총액:
$247.92M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.42%
1개월 성능:
-15.45%
6개월 성능:
+60.34%
1년 성능:
+0.00%
1일 변동 폭
$2.71
$2.92
1주일 범위
$2.71
$3.26
52주 변동 폭
$1.42
$4.66
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
2.79 | 247.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
aTyr Pharma to Participate in April Investor Conferences - GlobeNewswire
Biotech Innovator aTyr Pharma Sets Key Investor Meetings at Premier Healthcare Conferences - Stock Titan
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - MarketScreener
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments - Markets Insider
Reviewing Atyr PHARMA (NASDAQ:ATYR) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations By Investing.com - Investing.com Australia
aTyr Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... - Yahoo Finance
aTyr Pharma shares fall as Q4 loss narrows - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... By GuruFocus - Investing.com Canada
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising Clinical Developments - GuruFocus.com
aTyr Pharma Reports 2024 Results and Strategic Progress - TipRanks
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations - Investing.com
aTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Es - GuruFocus.com
aTYR PHARMA INC SEC 10-K Report - TradingView
aTyr Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atyr Pharma: Q4 Earnings Snapshot - mySA
aTyr Pharma shares fall as Q4 loss narrows By Investing.com - Investing.com South Africa
ATYR PHARMA Earnings Results: $ATYR Reports Quarterly Earnings - Nasdaq
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - The Manila Times
aTyr Pharma Hits Major Phase 3 Milestone with $94M War Chest for Sarcoidosis Drug - StockTitan
aTyr Pharma’s efzofitimod shows promise in ILD treatment By Investing.com - Investing.com Canada
aTyr Pharma’s efzofitimod shows promise in ILD treatment - Investing.com India
aTyr Pharma Announces Publication Demonstrating - GlobeNewswire
aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - The Manila Times
Breakthrough: New Science Study Reveals How Efzofitimod Fights Chronic Inflammation - StockTitan
aTyr Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Atyr Pharma Shares Rise After Lung Disease Treatment Passes Safety Review - MarketWatch
aTyr Pharma: Attractive Buy Opportunity Amid Positive Phase 2 Data and Anticipated Phase 3 Catalysts - TipRanks
aTyr rises after safety update on lead program - Seeking Alpha
aTyr Pharma Announces Fourth Positive DSMB Review for - GlobeNewswire
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):